1. Home
  2. TMDX vs CPRX Comparison

TMDX vs CPRX Comparison

Compare TMDX & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TransMedics Group Inc.

TMDX

TransMedics Group Inc.

HOLD

Current Price

$67.93

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Logo Catalyst Pharmaceuticals Inc.

CPRX

Catalyst Pharmaceuticals Inc.

HOLD

Current Price

$31.17

Market Cap

3.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TMDX
CPRX
Founded
1998
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
3.4B
IPO Year
2019
2006

Fundamental Metrics

Financial Performance
Metric
TMDX
CPRX
Price
$67.93
$31.17
Analyst Decision
Buy
Strong Buy
Analyst Count
9
1
Target Price
$148.22
$35.00
AVG Volume (30 Days)
1.2M
2.3M
Earning Date
05-05-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
382.18
28.24
EPS
0.20
1.68
Revenue
$605,494,000.00
$119,072,803.00
Revenue This Year
$24.25
$9.20
Revenue Next Year
$18.75
$10.51
P/E Ratio
$362.75
$18.54
Revenue Growth
37.13
16.39
52 Week Low
$70.00
$19.05
52 Week High
$156.00
$32.56

Technical Indicators

Market Signals
Indicator
TMDX
CPRX
Relative Strength Index (RSI) 19.80 73.25
Support Level N/A $22.41
Resistance Level $131.86 $32.56
Average True Range (ATR) 5.31 1.30
MACD -3.88 0.30
Stochastic Oscillator 0.17 80.10

Price Performance

Historical Comparison
TMDX
CPRX

About TMDX TransMedics Group Inc.

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

About CPRX Catalyst Pharmaceuticals Inc.

Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.

Share on Social Networks: